Clinical trials: Premalignant
Cervical Intraepithelial Neoplasia
An Innovative Treatment for Cervical Precancer (UH3)
The purpose of this academic-industrial partnership will compare the CryoPen® and thermoablator to traditional CO2-based cryotherapy for the treatment of cervical precancer in low and middle income countries (LMICs) and…
- Trial name
- UH3 (NCT03084081)
- Testing
- CO2 standard therapy, CryoPen, Thermocoagulator
- Where
- 3 sites in China, Colombia and 1 more
- Volunteers
- 1,132 people
- Sponsor
- The Cleveland Clinic
Barrett Esophagus
OCT Pilot in Esophagus
This is a pilot study to test a newly developed optical coherence tomography (OCT) device to determine 1) whether adequate tissue contact can be attained to acquire high quality images, and 2) to identify if these images can…
- Trial name
- NCT03434834
- Testing
- optical coherence tomography
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Duke University
Extensive Photodamage, Actinic Keratosis
Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study
This project aims to treat field cancerization ( pre-skin cancers) in a manner that will reduce the future pre-skin cancers and non-melanoma skin cancers in patients with significant photodamage.
- Conditions
- Extensive Photodamage, Actinic Keratosis, History of Numerous Skin Cancers
- Trial name
- NCT02150863
- Testing
- Ultrapulse Carbon Dioxide Laser, Cellutome epidermal harvesting system
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Actinic Keratosis
Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery
The objective of this study is to evaluate the efficacy and safety of imiquimod cream versus placebo cream when used after cryosurgery in the treatment of actinic keratoses (AKs).
- Trial name
- NCT00894647
- Testing
- imiquimod cream
- Where
- 18 sites in United States, Canada
- Volunteers
- 247 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Actinic Keratoses
Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
The aim of this study is to assess the pharmacokinetics (PK) of the parent drug 5-aminolevulinic acid (ALA) and its active metabolite protoporphyrin IX (PpIX) during photodynamic therapy with 3 tubes of BF-200 ALA 10% gel…
- Trial name
- NCT04319159
- Testing
- BF-200 ALA and red light LED lamp
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Biofrontera Bioscience GmbH
Cervical Intraepithelial Neoplasia
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects
The purpose of this prospective, multi-centre, PMS cohort study was to monitor the safety of Cervarix, which is the first HPV vaccine licensed for use in China, to help prevent cervical cancer caused by HPV types 16 and 18.
- Trial name
- NCT03438006
- Testing
- Safety data collection (following routine vaccination)
- Where
- 7 sites in China
- Volunteers
- 3,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asymptomatic Multiple Myeloma
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma
The purpose of this study is to determine the safety and in vivo persistence and expansion of autologous and expansion of autologous, ex vivo expanded-natural killer(ENK) cells.
- Trial name
- NCT01884688
- Testing
- ENK Cell Infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Arkansas
Actinic Keratosis
To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis
The purpose of this study is to compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of actinic keratosis.
- Trial name
- NCT02385318
- Testing
- Ingenol Mebutate (Perrigo), Ingenol Mebutate (Reference)
- Volunteers
- 519 people
- Sponsor
- Padagis LLC
Gastroesophageal Reflux Disease (GERD)
Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Its Correlation With GERD
This study is proposed to evaluate the role of motoric dysfunctions and type of refluxate in GERD patients, analyzed the blood monocyte/macrophage phenotypes of gastroesophageal reflux diseases (GERD) patients.
- Trial name
- NCT02699060
- Testing
- Upper gastrointestinal endoscopy with biopsy and collection of refluxate, Esophageal high-resolution manometry and 24-h esophageal pH-impedance monitoring
- Where
- 2 sites in Russia
- Volunteers
- 68 people
- Sponsor
- Ivashkin Vladimir Trofimovich
Actinic Keratosis
Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy
The purpose of this research study is to evaluate the use of Biafine Cream on wounds created by removal of actinic keratosis using cryotherapy in a clinical setting.
- Trial name
- NCT00695578
- Testing
- Biafine, Polysporin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University
Actinic Keratosis
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than…
- Trial name
- NCT02952898
- Testing
- GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel
- Where
- 16 sites in United States
- Volunteers
- 665 people
- Sponsor
- Balmoral Medical company
High Risk Smoldering Multiple Myeloma
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
The purpose of this research study is to test whether the drug ibrutinib (trademark name: IMBRUVICA®) is effective at preventing the development of multiple myeloma in people who currently have smoldering myeloma.
- Trial name
- NCT02943473
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Actinic Keratosis
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment
- Trial name
- NCT02549339
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 383 people
- Sponsor
- LEO Pharma
Barrett Esophagus, Esophageal Adenocarcinoma
Rapid Assessment of Esophageal Adenocarcinoma Risk Test
This study aims to evaluate the acceptability of a new non-invasive screening device to test for Barrett's esophagus. The investigators will prospectively enroll 100 patients to undergo Cytosponge testing.
- Trial name
- REACT (NCT03366012)
- Testing
- Cytosponge
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Columbia University
Precancerous Condition
Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses
RATIONALE: Drugs used in chemotherapy, such as perillyl alcohol, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00608634
- Testing
- perillyl alcohol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- University of Arizona
Colon Cancer, Rectal Cancer
Endoscopic Optical Coherence Tomography for Screening and Diagnosis of Colorectal Precancerous and Malignant Polyps
Colorectal cancer arises from the mucosal layer of the colon. Current screening is performed by flexible endoscopy, which involves visual inspection of the mucosal lining of the colon and rectum with an optical camera mounted on…
- Conditions
- Colon Cancer, Rectal Cancer, Cancer of the Rectum, Cancer of the Colon
- Trial name
- NCT05179837
- Testing
- Optical coherence tomography probe
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Lymphoma, Precancerous/Nonmalignant Condition
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1.
- Trial name
- NCT00854581
- Testing
- PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Miami
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)…
- Trial name
- NCT04850846
- Testing
- Metformin XR
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma, Smoldering Multiple Myeloma
Imaging in MGUS, SMM and MM
Background: Recent studies have shown that the premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) have a high risk of progressing to multiple myeloma (MM).
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT01237054
- Testing
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and…
- Trial name
- NCT00896480
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 8 sites in Belgium, France
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline